Back

Prevalence of eligibility for dual GIP/GLP-1 receptor agonists among non-diabetic and overweight adults - a Portuguese community-based study

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in risk factors and prevention (1) Obesity Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Helena Santos Moreira

Sao Joao University Hospital Centre, Porto (Portugal)

6 More presentations in this session

Presentation thumbnail
The role of the triglyceride-glucose index as a predictor of coronary artery disease severity in young patients
Doctor A. Martins (Leiria, PT)
Abstract
Presentation thumbnail
Design of the asian diabetes outcomes prevention trial: biomarker-guided primary prevention and key protocol updates
Doctor C. Chandramouli (Singapore, SG)
Abstract
Presentation thumbnail
GLP-1 receptor agonist-induced post-procedural gastrointestinal and biliary complications in cardiothoracic surgery
Doctor Z. Wright (Winston Salem, US)
Abstract
Presentation thumbnail
Cardio-kidney-metabolic syndrome in the general population: patterns and sex-specific trajectories
Doctor R. Coenen Chelu (Rotterdam, NL)
Abstract
Presentation thumbnail
Glucose-lowering therapy in type 2 diabetes with heart failure vs high HF risk: missed opportunities for prognosis-modifying treatment
Associate Professor V. Medovchshikov (Aktobe, KZ)
Abstract

Access the full session

Session thumbnail
ePosters in risk factors and prevention (1)

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Obesity as a disease: focus on the heart
thumbnail
Congress Session
Obesity as a cardiovascular disease: integrated management
thumbnail
Webinar
Obesity management: implications for cardiovascular risk reduction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources